Clinical trial · Observational
Perfusion Assessment With Contrast-Enhanced EUS in Locally Advanced and Metastatic Pancreatic Cancer
Changes in Tumor Vascularity Depicted by Contrast-Enhanced Endoscopic Ultrasonography as a Predictor of Treatment Efficacy in Patients With Locally Advanced and Metastatic Pancreatic Cancer (PEACE)
NCT03513198CI-TRIAL-00032739PEACEunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with non-resectable pancreatic cancer have a poor prognosis.The analysis of prognostic factors before treatment may be helpful in selecting appropriate candidates for chemotherapy and determining treatment strategies. The aim of the PEACE study is to assess the vascularity of pancreatic malignant tumors using contrast-enhanced endoscopic ultrasonography and to clarify the prognostic value of tumor vascularity in patients with locally advanced and metastatic pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Cancer | Pancreatic Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Contrast-enhanced computed tomography (CT) | Diagnostic Test | — | UNRESOLVED |
| Contrast-enhanced endoscopic ultrasound (CE-EUS) | Other | — | UNRESOLVED |
| Endoscopic ultrasound elastography (EG-EUS) | Other | — | UNRESOLVED |
| Endoscopic ultrasound (including fine needle aspiration) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Non-resectable pancreatic cancer
- description
- All patients with a suspicion of pancreatic masses will undergo EUS (including EUS-FNA for confirmation of diagnosis). A positive cytological diagnosis will be taken as a final proof of malignancy of the pancreas mass. The diagnoses obtained by EUS-FNA will be further verified during a clinical follow-up of at least 6 months. Both pancreatic adenocarcinomas and pancreatic neuroendocrine tumors will be included. Endoscopic ultrasound (including fine needle aspiration for confirmation of diagnosis) with sequential contrast-enhanced endoscopic ultrasound and elastography endoscopic ultrasound and contrast-enhanced computed tomography will be performed before and 2 months after the first course of treatment
- interventionNames
- Diagnostic Test: Endoscopic ultrasound (including fine needle aspiration)
- Other: Contrast-enhanced endoscopic ultrasound (CE-EUS)
- Other: Endoscopic ultrasound elastography (EG-EUS)
- Diagnostic Test: Contrast-enhanced computed tomography (CT)
Primary outcomes (7)
- measure
- Change of Peak Enhancement (PE) from baseline to 2 months after the first course of treatment
- timeFrame
- baseline and 2 months after the first course of treatment
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 to 90 years old, men or women * Signed informed consent for CE-EUS, EG-EUS and FNA biopsy * The diagnosis of pancreatic cancer histologically confirmed by fine needle aspiration (FNA) with EUS * Both pancreatic adenocarcinoma and pancreatic neuroendocrine tumors will be included * Unresectable, locally advanced and/or metastatic disease. Exclusion Criteria: * Previous chemotherapy or radiotherapy * Resectable pancreatic tumors
References
Publications (10)
- BACKGROUNDLowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):197-209. doi: 10.1016/j.bpg.2005.10.001. PMID 16549324
- BACKGROUNDFolkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990 Jan 3;82(1):4-6. doi: 10.1093/jnci/82.1.4. No abstract available. PMID 1688381
- BACKGROUNDFidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994 Oct 21;79(2):185-8. doi: 10.1016/0092-8674(94)90187-2. No abstract available. PMID 7525076
- BACKGROUNDIkeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H, Miyake M. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer. 1999 Mar;79(9-10):1553-63. doi: 10.1038/sj.bjc.6690248. PMID 10188906
- BACKGROUNDSaftoiu A, Vilmann P, Bhutani MS. The role of contrast-enhanced endoscopic ultrasound in pancreatic adenocarcinoma. Endosc Ultrasound. 2016 Nov-Dec;5(6):368-372. doi: 10.4103/2303-9027.190932. PMID 28000627
- BACKGROUNDYamashita Y, Ueda K, Itonaga M, Yoshida T, Maeda H, Maekita T, Iguchi M, Tamai H, Ichinose M, Kato J. Tumor vessel depiction with contrast-enhanced endoscopic ultrasonography predicts efficacy of chemotherapy in pancreatic cancer. Pancreas. 2013 Aug;42(6):990-5. doi: 10.1097/MPA.0b013e31827fe94c. PMID 23851433
- BACKGROUNDSanchez MV, Varadarajulu S, Napoleon B. EUS contrast agents: what is available, how do they work, and are they effective? Gastrointest Endosc. 2009 Feb;69(2 Suppl):S71-7. doi: 10.1016/j.gie.2008.12.004. No abstract available. PMID 19179175
- Zhang X, Galardi E, Duquette M, Lawler J, Parangi S. Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin Cancer Res. 2005 Aug 1;11(15):5622-30. doi: 10.1158/1078-0432.CCR-05-0459.